{"name":"Chesapeake Urology Research Associates","slug":"chesapeake-urology-research-associates","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eligard (TM)","genericName":"Eligard (TM)","slug":"eligard-tm","indication":"Advanced prostate cancer","status":"marketed"}]}],"pipeline":[{"name":"Eligard (TM)","genericName":"Eligard (TM)","slug":"eligard-tm","phase":"marketed","mechanism":"Eligard is a leuprolide acetate depot injection that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone production.","indications":["Advanced prostate cancer","Prostate cancer requiring androgen deprivation therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQOHNNeUJlTkppdzhBU3p6ZDhJazF4YzhUNXVaOUJiQVh3NWhKTGlIVU12czZ5TEJiYlUzVm9jVVNvamhXQWxOZ3RmemJLUER4em5sU0FuV0JwMUhPaUVqVW4xaHk4czVtOHVKa2tnNzdqbnhYU2pPTEJKZmstTDRJbHFCM1FoclJ6enZtRzFaY1Z4NnhsbWs4NnJTS2lpUHZmemdmMjNfZU42ZjVUWFVtSF82NkxaWlk5ZjRJSHpCWmFPUUtNYkxGOThucGpUdw?oc=5","date":"2025-11-19","type":"regulatory","source":"prnewswire.com","summary":"Chesapeake Oncology-Hematology Associates Joins Chesapeake Urology Associates - prnewswire.com","headline":"Chesapeake Oncology-Hematology Associates Joins Chesapeake Urology Associates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPYVZpb1UtWUdOOFhCWmI1MFpXM3NZSVdGOXFGc2k5NFZfUElLZmE4MWtGS2lheXpKMFdqQXBjNmkzVUs4UC0wU2VxSUh5MmtwRGxWQVZoNllDLUx1YlNJdGFELVYtaGJxRXFHb1oxQm1lWDR0NFo1VDBtWXBFcmF4aUloeWdmMnJCcW42azNrU09yMUdVTkcyNDl0TF9keWpfdXQxekJBVkpRNTdKczVIUm1zSEc1blQzNFhIUGY2S1RnMWRudGF4Xw?oc=5","date":"2014-11-07","type":"pipeline","source":"prnewswire.com","summary":"Bishoy A. Gayed, M.D., Urologic Oncologist, Joins Chesapeake Urology Associates - prnewswire.com","headline":"Bishoy A. Gayed, M.D., Urologic Oncologist, Joins Chesapeake Urology Associates","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}